Dyne Therapeutics tumbles after beginning $300 mln stock offering
DYN•Shares fall after proposed equity raise
** Shares of Dyne Therapeutics DYN.O down 14% to $20.50 post-market as co looks to raise equity
** Neuromuscular disease-focused DYN commences $300 mln stock offering
** Morgan Stanley, Jefferies and Evercore jt bookrunners, along with LifeSci Capital and Raymond James
** DYN shares ended up 1.6% at $23.83 on Tues, up 22% YTD
** Waltham, Massachusetts-based firm has ~165.3 mln shares outstanding for nearly $4 bln market cap
** 15 of 16 analysts rate the stock "strong buy" or "buy", 1 "hold"; median PT $40, per LSEG data
